Finance

Lists
AUPH:NASDAQ
Aurinia Pharmaceuticals Inc
$15.96
+0.09%
(+0.015) 1D
$16.08
+0.82% (+0.13)
Pre-market
Closed: Oct 1, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AUPH...
Open
$16.06
High
$16.06
Low
$15.95
Mkt. cap
2.12B
Avg. vol.
882.88K
Volume
5.06K
P/E ratio
6.97
52-wk high
$19.25
52-wk low
$10.90
EPS
$2.29
Beta
1.60
Shares outstanding
133.05M
No. of employees
128
Open
$16.06
High
$16.06
Low
$15.95
Mkt. cap
2.12B
Avg. vol.
882.88K
Volume
5.06K
P/E ratio
6.97
52-wk high
$19.25
52-wk low
$10.90
EPS
$2.29
Beta
1.60
Shares outstanding
133.05M
No. of employees
128
News stories
From web sources and news partners
TradingView
TradingView
·
25 minutes ago
S&P 500 futures add to gains, yields drop after jobs data
Breakingthenews.net
Breakingthenews.net
·
4 minutes ago
Wall Street rallies at open, Dow surges 350 pts
ChartMill
ChartMill
·
1 hour ago
Top S&P500 movers in Friday's pre-market session
Investor's Business Daily
Investor's Business Daily
·
3 hours ago
Twilio To Join S&P 500 Index
About Aurinia Pharmaceuticals Inc
CEO-
Employees128
Founded2012
HeadquartersEdmonton, Alberta, Canada
SectorBiotechnology
Websiteauriniapharma.com
Analyst ratings
Based on 3 analysts giving stock ratings to AUPH in the past 3 months
Buy
Buy
2
Hold
1
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for AUPH in the last 3 months.
Highest
Current $15.96
$21.00 (+31.54%)
Average
$18.00 (+12.75%)
Lowest
$16.00 (+0.22%)
Analyst
Recommendation
Action
Price target
Projected
Date
David Martin PhD
Bloom Burton
Buy
Upgraded
$21.00
+31.5%
08/20/2026
Stacy Ku
TD Cowen
Buy
Maintained
$17.00
+6.5%
08/19/2026
Douglas Miehm
RBC Capital
Hold
Maintained
$16.00
+0.2%
08/07/2026
Arthur He CFA
H.C. Wainwright
Buy
Reiterated
$17.00
+6.5%
02/27/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
73.47M
77.11M
77.70M
83.22M
Cost of goods sold
8.50M
40.55M
13.98M
18.30M
Cost of revenue
8.50M
40.55M
13.98M
18.30M
Research and development expenses
8.11M
-20.86M
-
1.31M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
26.18M
29.26M
22.03M
23.51M
Operating expense
35.22M
-6.37M
22.31M
18.58M
Total operating expenses
43.72M
34.18M
36.28M
36.88M
Operating income
29.74M
42.94M
41.42M
46.34M
Other non operating income
-
-
-
-
EBT including unusual items
31.96M
35.69M
43.92M
48.79M
EBT excluding unusual items
31.96M
35.69M
43.92M
48.79M
Income tax expense
411.00K
-175.10M
9.57M
11.37M
Effective tax rate
1.29%
-490.62%
21.79%
23.31%
Other operating expenses
929.00K
-14.77M
279.00K
-6.23M
Net income
31.55M
210.79M
34.36M
37.41M
Net profit margin
42.95%
273.35%
44.21%
44.96%
Earnings per share
0.23
1.53
0.25
0.28
Interest and investment income
3.32M
3.50M
3.52M
3.39M
Interest expense
-1.10M
-1.05M
-1.01M
-948.00K
Net interest expenses
2.22M
2.45M
2.50M
2.44M
Depreciation and amortization charges
-
-
-
-
EBITDA
34.61M
47.80M
46.24M
51.18M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps